134 related articles for article (PubMed ID: 33289508)
1. Identification of immune-based prostate cancer subtypes using mRNA expression.
Song J; Wang W; Yuan Y; Ban Y; Su J; Yuan D; Chen W; Zhu J
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33289508
[TBL] [Abstract][Full Text] [Related]
2. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value.
Liu J; Tan Z; He J; Jin T; Han Y; Hu L; Song J; Huang S
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33043974
[TBL] [Abstract][Full Text] [Related]
3. Immunogenomic Profiling and Classification of Prostate Cancer Based on HIF-1 Signaling Pathway.
Song J; Chen W; Zhu G; Wang W; Sun F; Zhu J
Front Oncol; 2020; 10():1374. PubMed ID: 32850440
[TBL] [Abstract][Full Text] [Related]
4. Genomic analysis and clinical implications of immune cell infiltration in gastric cancer.
Wu M; Wang Y; Liu H; Song J; Ding J
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32338286
[TBL] [Abstract][Full Text] [Related]
5. Immune response drives outcomes in prostate cancer: implications for immunotherapy.
Meng J; Zhou Y; Lu X; Bian Z; Chen Y; Zhou J; Zhang L; Hao Z; Zhang M; Liang C
Mol Oncol; 2021 May; 15(5):1358-1375. PubMed ID: 33338321
[TBL] [Abstract][Full Text] [Related]
6. Plasma cell subtypes analyzed using artificial intelligence algorithm for predicting biochemical recurrence, immune escape potential, and immunotherapy response of prostate cancer.
Xie X; Dou CX; Luo MR; Zhang K; Liu Y; Zhou JW; Huang ZP; Xue KY; Liang HY; Ouyang AR; Ma SX; Yang JK; Zhou QZ; Guo WB; Liu CD; Zhao SC; Chen MK
Front Immunol; 2022; 13():946209. PubMed ID: 36569837
[TBL] [Abstract][Full Text] [Related]
7. Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance.
Zheng K; Hai Y; Xi Y; Zhang Y; Liu Z; Chen W; Hu X; Zou X; Hao J
J Transl Med; 2023 Nov; 21(1):789. PubMed ID: 37936202
[TBL] [Abstract][Full Text] [Related]
8. Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer.
Arredouani MS; Lu B; Bhasin M; Eljanne M; Yue W; Mosquera JM; Bubley GJ; Li V; Rubin MA; Libermann TA; Sanda MG
Clin Cancer Res; 2009 Sep; 15(18):5794-802. PubMed ID: 19737960
[TBL] [Abstract][Full Text] [Related]
9. Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram.
Rui X; Shao S; Wang L; Leng J
BMC Cancer; 2019 Dec; 19(1):1179. PubMed ID: 31795990
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Immune Infiltration in HNC and Their Clinical Implications: A Gene Expression-Based Study.
Song J; Deng Z; Su J; Yuan D; Liu J; Zhu J
Front Oncol; 2019; 9():1285. PubMed ID: 31867268
[No Abstract] [Full Text] [Related]
11. Exploration and validation of the effects of robust co-expressed immune-related genes on immune infiltration patterns and prognosis in laryngeal cancer.
Zeng H; Huang Y; Chen L; Li H; Ma X
Int Immunopharmacol; 2020 Aug; 85():106622. PubMed ID: 32485354
[TBL] [Abstract][Full Text] [Related]
12. EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms.
Chang P; Chen S; Chang X; Zhu J; Tang Q; Ma L
Eur J Med Res; 2022 Jul; 27(1):115. PubMed ID: 35818069
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease.
Kamoun A; Cancel-Tassin G; Fromont G; Elarouci N; Armenoult L; Ayadi M; Irani J; Leroy X; Villers A; Fournier G; Doucet L; Boyault S; Brureau L; Multigner L; Diedhiou A; Roupret M; Compérat E; Blanchet P; de Reyniès A; Cussenot O
Ann Oncol; 2018 Aug; 29(8):1814-1821. PubMed ID: 29945238
[TBL] [Abstract][Full Text] [Related]
14. Immune Microenvironment and Response in Prostate Cancer Using Large Population Cohorts.
Ren X; Chen X; Zhang X; Jiang S; Zhang T; Li G; Lu Z; Zhang D; Wang S; Qin C
Front Immunol; 2021; 12():686809. PubMed ID: 34777331
[TBL] [Abstract][Full Text] [Related]
15. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
Bou-Dargham MJ; Sha L; Sang QA; Zhang J
BMC Cancer; 2020 Jun; 20(1):572. PubMed ID: 32552802
[TBL] [Abstract][Full Text] [Related]
16. Correlation analysis between immune-related genes and cell infiltration revealed prostate cancer immunotherapy biomarkers linked to T cells gamma delta.
Niu W; Zhang T; Ma L
Sci Rep; 2023 Feb; 13(1):2459. PubMed ID: 36774376
[TBL] [Abstract][Full Text] [Related]
17. Identification of docetaxel-related biomarkers for prostate cancer.
Peng Y; Dong S; Yang Z; Song Y; Ding J; Hou D; Wang L; Zhang Z; Li N; Wang H
Andrologia; 2021 Aug; 53(7):e14079. PubMed ID: 34021502
[TBL] [Abstract][Full Text] [Related]
18. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
19. The establishment of immune infiltration based novel recurrence predicting nomogram in prostate cancer.
Meng J; Liu Y; Guan S; Fan S; Zhou J; Zhang M; Liang C
Cancer Med; 2019 Sep; 8(11):5202-5213. PubMed ID: 31355524
[TBL] [Abstract][Full Text] [Related]
20. Extended application of genomic selection to screen multiomics data for prognostic signatures of prostate cancer.
Li R; Wang S; Cui Y; Qu H; Chater JM; Zhang L; Wei J; Wang M; Xu Y; Yu L; Lu J; Feng Y; Zhou R; Huang Y; Ma R; Zhu J; Zhong W; Jia Z
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32898860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
